speaker-icon

Latest Posts

Innoplexus-AIO-partnership

2

Jan 24

Innoplexus and AIO Studien gGmbH are jointly announcing the start of a pilot project as part of the AIO data hub initiative

January 02, 2024 - Innoplexus and Amrit AG, members of the Partex NV Group, providers of innovative technology for health...
Read More
anavex_partex_partnership_Innoplexus

27

Jun 23

Strategic partnership announcement: Innoplexus holding company Partex NV is pleased to announce a one-of-its-kind collaboration with Anavex Life science corp. for Artificial Intelligence (AI) enabled drug development and healthcare sales marketing

Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to...
Read More

Innoplexus wins Horizon Interactive Gold Award for Curia App

Read More

Archives: News

Innoplexus-AIO-partnership

Innoplexus and AIO Studien gGmbH are jointly announcing the start of a pilot project as part of the AIO data hub initiative

January 02, 2024 – Innoplexus and Amrit AG, members of the Partex NV Group, providers of innovative technology for health data analysis, and AIO Studien gGmbH, with expertise in clinical studies and registries for oncology research, are jointly announcing the start of a pilot project as part of the AIO data hub initiative. This pilot …

Innoplexus and AIO Studien gGmbH are jointly announcing the start of a pilot project as part of the AIO data hub initiative Read More »

anavex_partex_partnership_Innoplexus

Strategic partnership announcement: Innoplexus holding company Partex NV is pleased to announce a one-of-its-kind collaboration with Anavex Life science corp. for Artificial Intelligence (AI) enabled drug development and healthcare sales marketing

Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce their strategic partnership, aimed at revolutionizing the biopharma industry. By leveraging Partex’s proprietary AI (Artificial Intelligence) technology and Anavex’s innovative precision medicine drug development platform, we seek to enhance patient outcomes and reshape the …

Strategic partnership announcement: Innoplexus holding company Partex NV is pleased to announce a one-of-its-kind collaboration with Anavex Life science corp. for Artificial Intelligence (AI) enabled drug development and healthcare sales marketing Read More »

Kittu-Press-Release

AI supports targeted therapy recommendations fortumor diseases – BMBF funds joint research projectat University Medical Center Mainz with 2.53 millionEuros

The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary medical exchange, there are so-called tumor boards, in which the physicians discuss the treatment strategy. For this purpose, a large amount of medical data is available for each individual patient, which must be evaluated individually …

AI supports targeted therapy recommendations fortumor diseases – BMBF funds joint research projectat University Medical Center Mainz with 2.53 millionEuros Read More »

Innoplexus-Innovatrix-partnership

Innoplexus and Innovatrix capital partner to bring about new risk-transfer solutions for the life science industry

Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning (ML) to bring about new risk-transfer solutions for the life science industry. Eschborn, Germany/London, U.K., 27 July 2022Innoplexus AG is pleased to announce that an agreement for a strategic partnership with Innovatrix Capital Ltd. has …

Innoplexus and Innovatrix capital partner to bring about new risk-transfer solutions for the life science industry Read More »

Innoplexus-inflection-biosciences-joint-pr

Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence

Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30, 2022 – Innoplexus, a global leader in AI-based drug discovery and development, and Inflection Biosciences Ltd., an innovative biotechnology company focused upon developing innovative small molecule therapeutics for the treatment of cancer, autoimmune and …

Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence Read More »

Innoplexus-Parexel-Expand-Capabilities

Innoplexus and Parexel Expand Capabilities of COVID-19 Information Platform

COVID-19 Clearinghouse is the go-to platform for directly accessing the latest information and research about the coronavirus and COVID-19. ESCHBORN, Germany, Boston, M.A. and Durham, N.C., May 11, 2021 – Innoplexus, a global leader in AI-based drug discovery and development, and Parexel, a leading global clinical research organization, have expanded the features and functionality of their COVID-19 Clearinghouse platform …

Innoplexus and Parexel Expand Capabilities of COVID-19 Information Platform Read More »

parexel_clearinghouse

Parexel and Innoplexus Unveil Single Source of COVID-19 Information for Researchers, Sponsors and Patients During the Pandemic

COVID-19 Clearinghouse enables direct access to latest COVID-19 datasets, publications, research and clinical trials BOSTON and DURHAM, N.C. and ESCHBORN, Germany, Sept. 24, 2020 (GLOBE NEWSWIRE) — Parexel, a leading provider of solutions to accelerate the development and delivery of innovative new therapies to market to improve world health, from Clinical through Commercialization, in collaboration …

Parexel and Innoplexus Unveil Single Source of COVID-19 Information for Researchers, Sponsors and Patients During the Pandemic Read More »

google_pharma_industry

Wie das „Google der Pharmaindustrie“ den Kampf gegen Corona gewinnen will

Die Eschborner Firma Innoplexus ist so etwas wie das Google für die Pharmaindustrie. Firmenchef Gunjan Bhardwaj erklärt, wie künstliche Intelligenz beim Kampf gegen Covid-19 und Krebs helfen kann. Eine Prognose, wann ein wirksames Mittel auf den Markt kommen kann, wagt er nicht. Beim Börsengang sieht das aber schon anders aus. WELT: Herr Bhardwaj, Ihr Unternehmen Innoplexus …

Wie das „Google der Pharmaindustrie“ den Kampf gegen Corona gewinnen will Read More »